{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:45:33Z","timestamp":1789685133351,"version":"4.0.1"},"reference-count":45,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2000,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To review the pharmacology, pharmacokinetics, efficacy, and tolerability of reboxetine in the treatment of major depressive illness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>A MEDLINE search restricted to English-language literature was conducted (1966 to July 1999). Abstracts and posters presented at meetings were also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION\/STUDY SELECTION:<\/jats:title>\n                    <jats:p>Studies currently available were conducted in Europe. Data from clinical trials were reviewed to gather information specific to efficacy analysis, pharmacokinetic parameters, tolerability profiles, and drug\u2014drug interactions. Information on reboxetine was compared with other antidepressant therapies when appropriate data were available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Reboxetine is a selective norepinephrine reuptake inhibitor shown to be an effective agent in the treatment of major depressive illness. In clinical trials, reboxetine was effective in decreasing mean total scores of the Hamilton Rating Scale for Depression in adult populations. Improvements were similar between reboxetine and desipramine and imipramine, as well as fluoxetine. Reboxetine is relatively well tolerated, with insomnia, sweating, constipation, and dry mouth being commonly reported adverse events. Hypotension and urinary hesitancy occur at lower rates than with the tricyclics, and compared with fluoxetine, reboxetine is associated with lower rates of nausea, somnolence, and diarrhea. Dosage adjustments may be appropriate in elderly patients and those with renal and hepatic impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Reboxetine has received two letters of approval from the Food and Drug Administration for the treatment of major depression in adults. Upon completion of an additional US clinical study, reboxetine is likely to become a first-line agent in the management of depressive illness and a promising alternative for patients who have failed treatment with or do not tolerate serotonergic antidepressants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.19335","type":"journal-article","created":{"date-parts":[[2003,6,3]],"date-time":"2003-06-03T16:49:01Z","timestamp":1054658941000},"page":"1302-1312","source":"Crossref","is-referenced-by-count":51,"title":["Reboxetine: A Selective Norepinephrine Reuptake Inhibitor for the Treatment of Depression"],"prefix":"10.1177","volume":"34","author":[{"given":"Ann C","family":"Scates","sequence":"first","affiliation":[{"name":"Ann C Scates PharmD, Drug Information Specialist, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Murali","family":"Doraiswamy","sequence":"additional","affiliation":[{"name":"P Murali Doraiswamy MD, Director of Clinical Trials and Associate Professor, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2000,11,1]]},"reference":[{"key":"bibr-bibr1-aph.19335","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1994.03950010008002"},{"key":"bibr-bibr2-aph.19335","first-page":"405","volume":"54","author":"Greenberg PE","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"bibr-bibr3-aph.19335","first-page":"509","volume":"7","author":"Schildkraut JJ","year":"1965","journal-title":"J Neuropsychiatry Clin Neurosc"},{"key":"bibr-bibr4-aph.19335","first-page":"646","volume":"38","author":"Zarcone VP","year":"1977","journal-title":"Dis Nerv Syst"},{"key":"bibr-bibr5-aph.19335","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1600001"},{"key":"bibr-bibr6-aph.19335","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(81)90172-2"},{"key":"bibr-bibr7-aph.19335","first-page":"40","volume":"52","author":"Nierenberg AA","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"bibr-bibr8-aph.19335","first-page":"249","volume":"55","author":"Vanderhoff BT","year":"1997","journal-title":"Am Fam Physician"},{"key":"bibr-bibr9-aph.19335","unstructured":"Wong EHF, Graveel CR, Kagey ML, Cafagna N, Smith MW. Pharmacological selectivity of reboxetine: a selective noradrenaline reuptake inhibitor (poster). Presented at American College of Neuropsychopharmacology Meeting, Wai Koloa, Hawaii, December 8\u201312, 1997."},{"key":"bibr-bibr10-aph.19335","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1077(199802)13:1+<S13::AID-HUP979>3.0.CO;2-6"},{"key":"bibr-bibr11-aph.19335","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90403-5"},{"key":"bibr-bibr12-aph.19335","first-page":"7","volume":"53","author":"Tulloch IF","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"bibr-bibr13-aph.19335","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)00417-3"},{"key":"bibr-bibr14-aph.19335","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199901)20:1<53::AID-BDD157>3.0.CO;2-P"},{"key":"bibr-bibr15-aph.19335","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)00414-8"},{"key":"bibr-bibr16-aph.19335","first-page":"14","volume":"54","author":"Preskorn SH","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"bibr-bibr17-aph.19335","volume-title":"Prozac (fluoxetine)","year":"1998"},{"key":"bibr-bibr18-aph.19335","volume-title":"Zoloft (sertraline)","year":"1997"},{"key":"bibr-bibr19-aph.19335","volume-title":"Effexor XR (venlafaxine)","year":"1998"},{"key":"bibr-bibr20-aph.19335","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199610)17:7<623::AID-BDD978>3.0.CO;2-S"},{"key":"bibr-bibr21-aph.19335","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510160603"},{"key":"bibr-bibr22-aph.19335","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189965"},{"key":"bibr-bibr23-aph.19335","unstructured":"Wynalda MA, Grossi P, Speed W, Howard MR, Hauer MJ, Wienkers LC. Cytochrome P450\u2013mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes (abstract). Presented at American Association of Pharmaceutical Scientists Annual Meeting, November 14\u201319, 1998, San Francisco, California."},{"key":"bibr-bibr24-aph.19335","unstructured":"Davies DS, Murray S, Edwards RJ, Boobis AR. Inhibitory potential of reboxetine on major drug metabolizing forms of P450 in humans (abstract). Presented at American College of Neuropsychopharmacology Meeting, Wai Koloa, Hawaii, December 8\u201312, 1997."},{"key":"bibr-bibr25-aph.19335","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022009251"},{"key":"bibr-bibr26-aph.19335","unstructured":"Fleishaker JC, Wong EHF. Pharmacokinetics of reboxetine in elderly volunteers and depressed patients (poster no. 60). Presented at European College of Neuropsychopharmacology Meeting, Paris, France, October 31\u2013November 4, 1998."},{"key":"bibr-bibr27-aph.19335","volume-title":"Depression in primary care: volume 2. Treatment of major depression. Clinical practice guideline, number 5","author":"Depression Guideline Panel","year":"1993"},{"key":"bibr-bibr28-aph.19335","first-page":"28","volume":"52","author":"Kupfer DJ","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"bibr-bibr29-aph.19335","volume-title":"Diagnostic and statistical manual of mental disorders","year":"1980","edition":"3"},{"key":"bibr-bibr30-aph.19335","volume-title":"Diagnostic and statistical manual of mental disorders","year":"1987","edition":"3"},{"key":"bibr-bibr31-aph.19335","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1077(199802)13:1+<S29::AID-HUP980>3.0.CO;2-D"},{"key":"bibr-bibr32-aph.19335","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)00418-5"},{"key":"bibr-bibr33-aph.19335","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.v59n0103","volume":"59","author":"Massana J","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"bibr-bibr34-aph.19335","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199903000-00003"},{"key":"bibr-bibr35-aph.19335","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200002000-00006"},{"key":"bibr-bibr36-aph.19335","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)00420-3"},{"key":"bibr-bibr37-aph.19335","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.143.1.18"},{"key":"bibr-bibr38-aph.19335","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0610"},{"key":"bibr-bibr39-aph.19335","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1166(200009)15:9<784::AID-GPS189>3.0.CO;2-Z"},{"key":"bibr-bibr40-aph.19335","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.19.1665"},{"key":"bibr-bibr41-aph.19335","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0710"},{"key":"bibr-bibr42-aph.19335","unstructured":"Versiani M. Overall efficacy and tolerability of reboxetine in comparative clinical trials of 2613 patients with depressive illness (poster). Presented at the European College of Neuropsychopharmacology Meeting, Paris, France, October 31\u2013November 4, 1998."},{"key":"bibr-bibr43-aph.19335","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.39016.x"},{"key":"bibr-bibr44-aph.19335","doi-asserted-by":"publisher","DOI":"10.1053\/cp.1999.v66.a101207"},{"key":"bibr-bibr45-aph.19335","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199918020-00007"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.19335","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.19335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:02:49Z","timestamp":1777374169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.19335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["10.1345\/aph.19335"],"URL":"https:\/\/doi.org\/10.1345\/aph.19335","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}